Magazine Article | July 7, 2017

Companies To Watch: GeNeuro

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Fighting MS and other diseases through a novel target — human endogenous retrovirus expression.

SNAPSHOT
GeNeuro is developing drugs for targeting a novel disease mechanism that is directly causal, not one indirectly related to the disease symptoms targeted by conventional drugs: human endogenous retrovirus (HERV) expression. GeNeuro’s lead program, for the drug coded GNbAC1, is in a Phase 2b trial for treating relapsing remitting MS, conducted in partnership with Servier, with sixmonth data expected in October this year. GNbAC1 is also in Phase 2 trials for Type 1 diabetes, with results expected in the second half of 2018.